Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis

ClinicalTrials.gov ID: NCT00220779

Public ClinicalTrials.gov record NCT00220779. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV Chromatography (IGIV-C), 10% Treatment on Relapses in Patients With Relapsing Remitting Multiple Sclerosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.

Study identification

NCT ID: NCT00220779
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Grifols Therapeutics LLC; Industry
Enrollment: 128 participants

Conditions and interventions

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 55 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2002 (Type not available)
Primary completion: Feb 2005 (Actual)
Completion: Feb 2005 (Actual)
Last update posted: Apr 27, 2016

2002 – 2005

United States locations

U.S. sites: 6
U.S. states: 4
U.S. cities: 6

Facility	City	State	ZIP	Site status
Barrow Neurological Institute at St. Joseph's Hospital and Medical Center	Phoenix	Arizona	85013	—
Northwest NeuroSpecialists, PLLC	Tucson	Arizona	85741-3537	—
The Mt. Sinai Medical Center, Department of Neurology	New York	New York	10029	—
SUNY Health Science Center at Stony Brook, Department of Neurology	Stony Brook	New York	11794-8121	—
Wake Forest University - School of Medicine	Winston-Salem	North Carolina	27157	—
Neurology Health Care Service, Fletcher Allen Health Care	Burlington	Vermont	05401	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00220779, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 27, 2016 · Synced Oct 22, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00220779 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →